| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/14/2011 | US20110172313 Image quality in the eye |
| 07/14/2011 | US20110172312 Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| 07/14/2011 | US20110172311 Compounds For Treating Human Papillomavirus |
| 07/14/2011 | US20110172310 Di-fluoro containing compounds as cysteine protease inhibitors |
| 07/14/2011 | US20110172309 Galenic formulations of organic compounds |
| 07/14/2011 | US20110172308 Antagonsim of PGF2a Receptor to Treat Hyertension Characterized by Activation of the Renin-Angiotensin-Aldosterone System |
| 07/14/2011 | US20110172306 Creatine ester pronutrient compounds and formulations |
| 07/14/2011 | US20110172305 Endocannabinoids for Enhancing Growth and Development in Infants |
| 07/14/2011 | US20110172303 Deacetylase inhibitors and uses thereof |
| 07/14/2011 | US20110172302 Methods of treating meibomian gland dysfunction |
| 07/14/2011 | US20110172301 Use of anti-oxidant compounds for muscle recovery |
| 07/14/2011 | US20110172300 Novel epigallocatechin gallate trimer and alpha-glucosidase inhibitor containing epigallocatechin gallate polymer |
| 07/14/2011 | US20110172299 Therapeutic substituted cyclopentanes |
| 07/14/2011 | US20110172298 Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol |
| 07/14/2011 | US20110172297 Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof |
| 07/14/2011 | US20110172296 Modulation of transforming growth factor-beta 1 expression |
| 07/14/2011 | US20110172295 METHODS AND COMPOSITIONS FOR THE REGULATION OF microRNA PROCESSING |
| 07/14/2011 | US20110172294 Cyclohexenyl nucleic acids analogs |
| 07/14/2011 | US20110172293 Methods and Compositions for Modulating Angiogenesis |
| 07/14/2011 | US20110172292 Antidote oligomers |
| 07/14/2011 | US20110172291 Rna interference for the treatment of gain-of-function disorders |
| 07/14/2011 | US20110172290 Isoforms of eIF-5A: Senescence-induced eIF5A; Wounding-induced elF-5A; Growth elF-5A; and DHS |
| 07/14/2011 | US20110172289 Minor groove binder (mgb)-oligonucleotide mirna antagonists |
| 07/14/2011 | US20110172288 Compositions and Methods for the Identification, Assessment, Prevention and Therapy of Thymic Lymphoma or Hamartomatous Tumours |
| 07/14/2011 | US20110172287 Compositions and methods for inhibiting tumor growth and metastasis |
| 07/14/2011 | US20110172286 Cd44 splice variants in neurodegenerative diseases |
| 07/14/2011 | US20110172285 Proteasome inhibitors |
| 07/14/2011 | US20110172284 Methods for treating spinal muscular atrophy |
| 07/14/2011 | US20110172283 Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators |
| 07/14/2011 | US20110172282 Use of spiro-oxindole compounds as therapeutic agents |
| 07/14/2011 | US20110172281 Anti-Viral Drugs for Treatment of Arenavirus Infection |
| 07/14/2011 | US20110172280 Substituted Benzimidazoles |
| 07/14/2011 | US20110172279 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| 07/14/2011 | US20110172278 Compounds and methods for modulating g protein-coupled receptors |
| 07/14/2011 | US20110172277 Pirfenidone therapy and inducers of cytochrome p450 |
| 07/14/2011 | US20110172275 Pyrrole compounds |
| 07/14/2011 | US20110172274 Fluoro-substituted 3,4-diaryl-4,5-dihydro-1h-pyrazole-1-carboxamidine derivatives having cb1-antagonistic activity |
| 07/14/2011 | US20110172273 Methods of treating myelodysplastic syndromes using lenalidomide |
| 07/14/2011 | US20110172272 Benzisoxazoles |
| 07/14/2011 | US20110172271 Urinary Triaosylceramide (GB3) as a Marker of Cardiac Disease |
| 07/14/2011 | US20110172270 2-'4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatment of obesity |
| 07/14/2011 | US20110172269 Antioxidant combinations for use in feed rations to increase milk production and milk fat |
| 07/14/2011 | US20110172268 Mechanism-based small-molecule parasite inhibitors |
| 07/14/2011 | US20110172267 TSH receptor antagonizing tetrahydroquinoline compounds |
| 07/14/2011 | US20110172266 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 07/14/2011 | US20110172265 Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| 07/14/2011 | US20110172264 Nicotinic acetylcholine receptor modulators |
| 07/14/2011 | US20110172263 Indole derivatives as crth2 receptor antagonists |
| 07/14/2011 | US20110172262 Compositions and methods for treating epilepsy |
| 07/14/2011 | US20110172261 DIBENZO[f,h]ISOQUINOLINE DERIVATIVES |
| 07/14/2011 | US20110172260 Methods of providing weight loss therapy in patients with major depression |
| 07/14/2011 | US20110172259 Dosage form containing oxycodone and naloxone |
| 07/14/2011 | US20110172258 Indene derivatives as pharmaceutical agents |
| 07/14/2011 | US20110172257 (poly) aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents |
| 07/14/2011 | US20110172256 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| 07/14/2011 | US20110172255 Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists |
| 07/14/2011 | US20110172254 Folate receptor binding conjugates of antifolates |
| 07/14/2011 | US20110172253 Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines |
| 07/14/2011 | US20110172252 Triazolo[4,5-d]pyramidine derivatives and their use as purine receptor antagonists |
| 07/14/2011 | US20110172251 Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| 07/14/2011 | US20110172250 Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists |
| 07/14/2011 | US20110172249 Method for improving absorbability of preparation, and preparation having improved absorbability |
| 07/14/2011 | US20110172248 Substituted heteroarylamide analogs as mglur5 negative allosteric modulators and methods of making and using the same |
| 07/14/2011 | US20110172247 Substituted heteroarylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same |
| 07/14/2011 | US20110172246 1-(2-phenoxymethylphenyl)piperazine compounds |
| 07/14/2011 | US20110172245 Heterocyclic compound and use thereof |
| 07/14/2011 | US20110172244 Compounds and compositions as modulators of gpr119 activity |
| 07/14/2011 | US20110172243 Use of azaperone for reducing antibiotic usage |
| 07/14/2011 | US20110172242 Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| 07/14/2011 | US20110172241 Benzazole analogues and uses thereof |
| 07/14/2011 | US20110172240 Fatty acid fumarate derivatives and their uses |
| 07/14/2011 | US20110172239 Compounds, Compositions and Methods for the Treatment of Amyloid Diseases and Synucleinopathies such as Alzheimer's Disease, Type 2 Diabetes and Parkinson's Disease |
| 07/14/2011 | US20110172238 Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| 07/14/2011 | US20110172237 Quinuclidine derivatives as muscarinic m3 receptor antagonists |
| 07/14/2011 | US20110172236 Substituted aryl sulfone derivatives as calcium channel blockers |
| 07/14/2011 | US20110172235 Substituted triazolophthalazine derivatives |
| 07/14/2011 | US20110172234 Methods and compositions of trail-death receptor agonists/activators |
| 07/14/2011 | US20110172233 Sonic hedgehog modulators |
| 07/14/2011 | US20110172232 Aminoacyl prodrugs as an active pharmaceutical ingredient for thromboembolic disorders |
| 07/14/2011 | US20110172231 2,4- diaminopyrimidine derivatives |
| 07/14/2011 | US20110172230 Urea compound or salt thereof |
| 07/14/2011 | US20110172229 Modulators of atp-binding cassette transporters |
| 07/14/2011 | US20110172228 Kinase inhibitors and methods of use |
| 07/14/2011 | US20110172227 Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same |
| 07/14/2011 | US20110172226 Novel hydrazide containing taxane conjugates |
| 07/14/2011 | US20110172225 Antifungal agents |
| 07/14/2011 | US20110172224 Novel heterocycles |
| 07/14/2011 | US20110172223 Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers |
| 07/14/2011 | US20110172222 Oxazolidinones for the Treatment of Inflammatory Conditions of the Gastrointestinal Tract |
| 07/14/2011 | US20110172221 Annellated 4-(indazolyl)-1,4-dihydropyridine derivatives and methods of use thereof |
| 07/14/2011 | US20110172220 Discodermolide analogues and methods of their use |
| 07/14/2011 | US20110172219 Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors |
| 07/14/2011 | US20110172218 Cgrp antagonists |
| 07/14/2011 | US20110172217 Ring-fused morpholine derivative having pi3k-inhibiting activity |
| 07/14/2011 | US20110172216 Pyrazolopyrimidine pi3k inhibitor compounds and methods of use |
| 07/14/2011 | US20110172215 Benzene Sulfonamide Thiazole And Oxazole Compounds |
| 07/14/2011 | US20110172214 Use of targeted nitroxide agents in preventing, mitigating and treating radiation injury |
| 07/14/2011 | US20110172213 Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| 07/14/2011 | US20110172212 Amine-based compound and use thereof |
| 07/14/2011 | US20110172211 Transnasal Anticonvulsive Pharmaceutical Composition Comprising Poorly Soluble Anticonvulsant |